IRB Study Number 22-1241
Status Recruiting
Phase Phase 3
Institute Neurological Institute
Description
The purpose of the current Phase 3 study is to confirm the efficacy and safety of batoclimab in participants with gMG.
Inclusion Criteria
Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification Class II, III, or IVa at the Screening Visit.
Exclusion Criteria
Have experienced myasthenic crisis within 3 months of the Screening Visit.
Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study period.
Have any active or untreated malignant thymoma.
